Bladder Cancer Clinical Trial
Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer
Summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin, ifosfamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells.
PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating patients with metastatic urinary tract cancer that cannot be treated with surgery.
Full Description
OBJECTIVES:
Determine the efficacy of cisplatin, ifosfamide, and paclitaxel in patients with unresectable or metastatic urothelial cancer (nontransitional cell histologies).
OUTLINE: Patients receive paclitaxel IV over 3 hours and cisplatin IV over 1 hour on day 1 and ifosfamide IV over 1 hour on days 1-3. Filgrastim (G-CSF) is administered subcutaneously daily beginning on day 6 and continuing through day 17 or until blood counts recover. Treatment continues every 3 weeks for a maximum of 6 courses in the absence of stable or progressive disease after completion of course 2 or complete response after completion of course 4.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 2 years.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically proven unresectable or metastatic urothelial cancer
No transitional cell histologies
Bidimensionally measurable disease
PATIENT CHARACTERISTICS:
Age:
18 and over
Performance status:
Karnofsky 60-100%
Hematopoietic:
WBC at least 3,500/mm^3
Platelet count greater than 150,000/mm^3
Hepatic:
Bilirubin less than 2.0 mg/dL
Renal:
Creatinine less than 1.5 mg/dL OR
Creatinine clearance greater than 55 mL/min
Cardiovascular:
No New York Heart Association class III or IV heart disease
Other:
No other concurrent malignancy except basal cell skin cancer
PRIOR CONCURRENT THERAPY:
Biologic therapy
Not specified
Chemotherapy
No prior systemic chemotherapy
Endocrine therapy
Not specified
Radiotherapy
At least 3 weeks since prior radiotherapy
Surgery
Not specified
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10021, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.